United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 4

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 4 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderCo-Diagnostics · 48

Strongest available pathMerit · +26.3%

Widest latest marginStryker · 12.9%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CODX · Nasdaq

Co-Diagnostics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2012Salt Lake City, Utah$8.3M market cap

View full Companies Radar profile

48Cautious

Snapshot price$1.19as of page date

Monthly-close return-99.6%five-year window

FY2025 revenue$0.00BCo-Diagnostics, Inc.

Net margin-7533.6%FY2025

P/E snapshot-1.4xone ratio, not a verdict

Prism attention1.5%share across these five

Filing track recordRevenue, USD billions

-99.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -71.8%

52-week position1% through range

$0.94$46.50

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents2

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position3/100
Capital-event signal76/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2MMSI · Nasdaq

Merit

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Santa Rosa, California$5.41B market cap

View full Companies Radar profile

48Cautious

Snapshot price$90.68as of page date

Monthly-close return+26.3%five-year window

FY2025 revenue$1.52BMERIT MEDICAL SYSTEMS INC

Net margin8.5%FY2025

P/E snapshot37.3xone ratio, not a verdict

Prism attention60.4%share across these five

Filing track recordRevenue, USD billions

+41.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.0%

52-week position88% through range

$59.74$94.75

News mentions43.7K

Community mentions0partial coverage

U.S.-scope patents5017

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal75/100
Management stability90/100
Market position25/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 12 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PRCT · Nasdaq

PROCEPT BioRobotics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2009Redwood City, California$1.20B market cap

View full Companies Radar profile

48Cautious

Snapshot price$20.91as of page date

Monthly-close return-45.2%five-year window

FY2025 revenue$0.31BPROCEPT BioRobotics Corp

Net margin-31.0%FY2025

P/E snapshot-18.1xone ratio, not a verdict

Prism attention0.7%share across these five

Filing track recordRevenue, USD billions

+793.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 72.9%

52-week position16% through range

$16.66$42.43

News mentions492

Community mentions11partial coverage

U.S.-scope patents269

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal79/100
Management stability90/100
Market position0/100
Capital-event signal40/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SYK · NYSE

Stryker

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1941PLYMOUTH$121.75B market cap

View full Companies Radar profile

48Cautious

Snapshot price$317.4as of page date

Monthly-close return+20.4%five-year window

FY2025 revenue$25.12BSTRYKER CORP

Net margin12.9%FY2025

P/E snapshot32.9xone ratio, not a verdict

Prism attention37.1%share across these five

Filing track recordRevenue, USD billions

+46.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 10.1%

52-week position31% through range

$281.0$396.9

News mentions26.9K

Community mentions2.4Kpartial coverage

U.S.-scope patents10742

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position39/100
Capital-event signal28/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 7 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 135 M&A involvements, 18 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TNON · Nasdaq

Tenon Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2019Los Gatos, California$3.0M market cap

View full Companies Radar profile

48Cautious

Snapshot price$4.52as of page date

Monthly-close return-99.7%since April 2022

FY2025 revenue$0.00BTenon Medical, Inc.

Net margin-318.4%FY2025

P/E snapshot-0.4xone ratio, not a verdict

Prism attention0.3%share across these five

Filing track recordRevenue, USD billions

+470.8%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 78.7%

52-week position0% through range

$4.38$50.40

News mentions205

Community mentions0partial coverage

U.S.-scope patents67

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal66/100
Management stability90/100
Market position0/100
Capital-event signal62/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Merit

+26.3%

Stryker

+20.4%

PROCEPT BioRobotics

-45.2%

Co-Diagnostics

-99.6%

Tenon Medical

-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Stryker

$25.12B

Merit

$1.52B

PROCEPT BioRobotics

$0.31B

Tenon Medical

$0.00B

Co-Diagnostics

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Stryker

12.9%

Merit

8.5%

PROCEPT BioRobotics

-31.0%

Tenon Medical

-318.4%

Co-Diagnostics

-7533.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Merit

60.4%

Stryker

37.1%

Co-Diagnostics

1.5%

PROCEPT BioRobotics

0.7%

Tenon Medical

0.3%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Merit leads the conversation

It holds 60.4% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $1.52B.

Price path

Merit leads the available price paths

Its monthly-close return is +26.3% for the five-year window. At the other end, Tenon Medical is -99.7% for its since April 2022. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Stryker has the widest latest margin

Its FY2025 net margin is 12.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

PROCEPT BioRobotics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -18.1x while its five-year window price return is -45.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CODX

Co-Diagnostics

1,074available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+104.3%190 latest 12m vs 93 prior 12m

Machine-classified coverage tone

83.2% positive+7.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

pcr testing 19molecular diagnostics 19stock price 17stock performance 16earnings report 13share price 13rt-pcr diagnostics 12rapid antigen tests 12

Keyword tag occurrences in available Prism news records.

Coverage: 2011-04-01–2026-06-03 · trend and themes shown through 2026-06

Areas of research · MMSI

Merit

43,699available Prism news records

Prism top themes

Leadership & governance

165

Legal, arbitration & regulatory

120

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-25.3%4,534 latest 12m vs 6,066 prior 12m

Machine-classified coverage tone

80.4% positive+4.9 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

college entrance exams 455admissions testing 421master's admission 305graduate admission criteria 274global tournaments 167exam prep courses 112academic tenure 108faculty advancement 108

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-01 · trend and themes shown through 2026-08

Areas of research · SYK

Stryker

26,860available Prism news records

Prism top themes

Price action & investor response

301

Capital allocation & transactions

255

Leadership & governance

195

Earnings & financial performance

170

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+8.8%3,745 latest 12m vs 3,441 prior 12m

Machine-classified coverage tone

63.8% positive-13.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cyber espionage 233digital sabotage 182state-sponsored hacking 167electronic warfare 153critical infrastructure attacks 140military parades 135military funerals 105robotic surgery 105

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SYK

Stryker

2,363 mentions

Workplace and hiring

1,114

Products, pricing and logistics

489

Stock and valuation

223

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 2,363 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CODX

Co-Diagnostics

through 2026-04-02

Earnings releases 18Regulatory 3Listing / IPO 2Leadership changes 1

2026-04-02
Regulatory
The parallel pursuit of commercial expansion in India, South Asia, and Saudi Arabia, alongside ongoing US regulatory review of the Co-Dx PCR platform, represents a geographically ambitious but financially stretched multi-front strategy for a company of this size.
2025-10-28
Listing / IPO
In a separate filing, Co-Diagnostics disclosed an at-the-market equity offering program of up to $10 million through an Equity Distribution Agreement with Maxim Group LLC.
2025-08-15
Earnings releases
Revenue of $0.2 million , which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MMSI

Merit

through 2026-04-02

Earnings releases 35M&A 13Asset acquisitions 6Leadership changes 4Company announcements 1

2026-04-02
M&A
Merit Medical Systems has purchased US-based View Point Medical through a merger transaction, making the latter a wholly owned subsidiary.
2026-02-24
Earnings releases
Merit delivered better-than-expected revenue and financial results in the fourth quarter
2025-10-16
Asset acquisitions
Merit Medical Systems, Inc. (NASDAQ: MMSI) has agreed to acquire the C2 CryoBalloon technology and related assets from Pentax Medical, a division of HOYA Corporation, for up to USD 22 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRCT

PROCEPT BioRobotics

through 2025-11-04

Earnings releases 21Listing / IPO 4Leadership changes 1

2025-11-04
Earnings releases
Total revenue for the third quarter of 2025 was $83.3 million, an increase of 43% compared to the prior year period.
2025-10-31
Leadership changes
Larry Wood, the corporate vice president who helped build Edwards’ market-leading transcatheter aortic valve replacement business in his two decades with the company, left in September to become CEO of Procept BioRobotics.
2024-10-28
Listing / IPO
PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SYK

Stryker

through 2026-05-01

Earnings releases 64M&A 29Leadership changes 14Company announcements 10Business contracts 4

2026-05-01
Earnings releases
Stryker reported sales of $6 billion in the quarter, representing year-over-year growth of 2.6%.
2026-03-26
Company announcements
Medical device maker Stryker said on Thursday its operations were steadily improving towards full capacity, after a cyberattack caused widespread disruption to its business.
2026-01-06
Asset acquisitions
VB Spine completed the acquisition of Stryker’s spine implant manufacturing facility in Cestas, France.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TNON

Tenon Medical

through 2026-03-21

Earnings releases 16Leadership changes 2Company announcements 1

2026-03-21
Earnings releases
record full-year revenue of $3.9 million, up 20% from 2024, supported by what he described as “strong second-half momentum.”
2024-08-27
Leadership changes
Tenon Medical, Inc. (NASDAQ:TNON) ('Tenon Medical' or the 'Company'), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has appointed Kevin Williamson as Chief Financial Officer.
2023-06-14
Company announcements
Tenon Medical, Inc. announced the pricing of its public offering of 10,000,000 units, with each unit consisting of one share of common stock and two warrants, each warrant to purchase one share of common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 16–23. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Co-Diagnostics leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open Co-Diagnostics in Companies Radar

Scale and margin leadership sit with Stryker and Stryker

Stryker has the largest displayed latest revenue at $25.12B; Stryker has the widest displayed latest margin at 12.9%.

Open Stryker in Companies Radar

Comparisons

Strongest versus weakest available price path

Merit is +26.3% for its five-year window; Tenon Medical is -99.7% for its since April 2022.

Open Merit in Companies Radar Open Tenon Medical in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $25.12B for Stryker to $0.00B for Co-Diagnostics. Entity and filing-period labels remain visible on the company cards.

Open Stryker in Companies Radar Open Co-Diagnostics in Companies Radar

Anomalies

Stryker has the widest attention-readiness rank gap

It ranks #2 by measured news attention (37.1%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Stryker in Companies Radar

PROCEPT BioRobotics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +793.6% while its available monthly-close return is -45.2%. The signs differ, but the two measures cover different windows and do not establish causality.

Open PROCEPT BioRobotics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Merit's 60.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Merit in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Co-Diagnostics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open Co-Diagnostics in Companies Radar

Stress-test the largest divergence before forming a view

Compare PROCEPT BioRobotics's profile with Merit's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open PROCEPT BioRobotics in Companies Radar Open Merit in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.